Stock Forecast

  Aurinia Pharmaceuticals Inc. ( AUPH) Stock. Should you Buy or Sell?    $ 7.26

0.44 (5.71 %)



Aurinia Pharmaceuticals Inc. Analysis

Updated on 10-09-2022
Symbol AUPH
Price $7.26
Beta 0.942
Volume Avg. $2.81 M
Market Cap $1.03 B
52 Week Range $6.28 - $33.972


Aurinia Pharmaceuticals Inc. opened the day at $7.26 which is +'5.71 % on yesterday's close. Aurinia Pharmaceuticals Inc. has a 52 week high of $33.972 and 52 week low of $6.28, which is a difference of $27.692. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.03 B and total net profit is $45605000 which means the company is trading at 22.59 times profit to market capitalization. Theoretically, if you were to buy Aurinia Pharmaceuticals Inc. for $1.03 B, it would take 15 years to get your money back. Aurinia Pharmaceuticals Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Aurinia Pharmaceuticals Inc. Stock Forecast - Is Aurinia Pharmaceuticals Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -6.581
Dividend Yiel 0.000
Net Profit Margin -1.783


Valuing Aurinia Pharmaceuticals Inc.


Price Book Value Ratio 2.434 Price To Book Ratio 2.434
Price To Sales Ratio 11.735 Price Earnings Ratio -6.581


How liquid is Aurinia Pharmaceuticals Inc.


Current Ratio 13.088
Quick Ratio 11.838


Debt


Debt Ratio 0.121 Debt Equity Ratio 0.138
Long Term Debt To Capitalization 0.017 Total Debt To Capitalization 0.019



Latest news about Aurinia Pharmaceuticals Inc.


Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model

LUPKYNIS revenues and company net losses are tracking better than my valuation model predicts -- and new European revenues are on the horizon. However, expenses continue to rise, which is contrary to my modelling.

Date : 15/08/2022

Aurinia Pharmaceuticals Inc's (AUPH) CEO Peter Greenleaf on Q2 2022 Results - Earnings Call Transcript

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants DeDe Sheel – Vice President-Investor Relations Peter Greenleaf – President and Chief Executive Officer Joe Miller – Chief Financial Officer Neil Solomons – Chief Medical Officer Conference Call Participants Ed Arce – HC Wainwright Justin Kim – Oppenheimer Olivia Brayer – Cantor Fitzgerald Sahil Dhingra – RBC Operator Greetings, and welcome to Aurinia Pharmaceuticals Second Quarter 2022 Financial and Operational Results Conference Call. At this time all participants are in listen-only mode.

Date : 04/08/2022

Why Aurinia Pharmaceuticals Stock Briefly Spiked Today

Investors embraced the biotech's second-quarter results.

Date : 04/08/2022

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -13.64% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Date : 04/08/2022

Why Aurinia Pharmaceuticals Stock Is Sliding Today

An analyst downgraded the stock.

Date : 27/07/2022





About Aurinia Pharmaceuticals Inc.


CEO : Mr. Peter Greenleaf
Sector : Healthcare
Industry : Biotechnology

Website : https://www.auriniapharma.com

Exchange : NASDAQ Global Market

Description :

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.


My Newsletter

Sign Up For Updates & Newsletters